Brief: Bristol-Myers Spokesperson Says Co Implemented A Voluntary Pause To Review Clinical Data Across Their Zola-Cel Program
01/09/2026 12:49
BRIEF-Bristol-Myers Spokesperson Says Co Implemented A Voluntary Pause To Review Clinical Data Across Their Zola-Cel Program Sept 1 (Reuters) - Bristol-Myers Squibb Company BMY.N:
BRISTOL-MYERS SQUIBB SPOKESPERSON - IMPLEMENTED A VOLUNTARY PAUSE TO REVIEW CLINICAL DATA ACROSS OUR ZOLA-CEL PROGRAM
Source text: [ID:]
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant